DaVita Inc. (NYSE:DVA) Short Interest Update

by · The Cerbat Gem

DaVita Inc. (NYSE:DVA – Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 4,300,000 shares, a decline of 14.9% from the September 30th total of 5,050,000 shares. Based on an average daily volume of 711,500 shares, the short-interest ratio is currently 6.0 days. Approximately 5.4% of the company’s shares are short sold.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 in the last quarter. Insiders own 2.00% of the company’s stock.

Institutional Trading of DaVita

Several institutional investors and hedge funds have recently bought and sold shares of the business. Harvard Management Co. Inc. bought a new stake in shares of DaVita during the second quarter worth approximately $55,115,000. Lazard Asset Management LLC boosted its stake in DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after purchasing an additional 153,008 shares during the period. Jupiter Asset Management Ltd. grew its holdings in DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock valued at $25,840,000 after buying an additional 111,311 shares in the last quarter. Point72 Asset Management L.P. bought a new position in DaVita during the 2nd quarter worth $9,615,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of DaVita during the third quarter worth $10,346,000. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group upped their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $159.00.

Get Our Latest Stock Report on DVA

DaVita Stock Up 1.0 %

Shares of NYSE:DVA traded up $1.63 during trading on Tuesday, hitting $158.68. 58,283 shares of the company were exchanged, compared to its average volume of 799,328. The stock has a market cap of $13.31 billion, a price-to-earnings ratio of 16.73, a P/E/G ratio of 0.90 and a beta of 0.87. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. DaVita has a fifty-two week low of $75.47 and a fifty-two week high of $168.50. The firm has a fifty day moving average price of $158.18 and a two-hundred day moving average price of $145.85.

DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.08 earnings per share. As a group, research analysts anticipate that DaVita will post 9.99 earnings per share for the current fiscal year.

About DaVita

(Get Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Articles